To fight the new strains, new drugs with more muscle are needed and, while a number of drugs are in later stages of clinical trial, this Initiative is needed to fill the early-stages pipeline.
"The emergence of drug resistant TB is of global consequence. While many organizations are investigating novel drugs and vaccines to minimize the burden of tuberculosis, clearly more work is required. Our contribution to this effort will be to leverage IDRI's internal capabilities, while leaning heavily on our public private-partnership with the Lilly Initiative," said Dr. Steve Reed, Founder and Head of IDRI's Research and Development Program.
The Lilly TB Drug Discovery Initiative's Board of Advisors includes Dr. Gail Cassell from Lilly; Dr. Barry Bloom, Dean of Harvard University School of Public Health; Dr. Queta Bond, President of Burroughs Wellcome Fund (ret.); Dr. Bruce Carter, Liaison to the Board of Directors for the TB Alliance; Dr. Paul Farmer, Partners In Health and Harvard Medical School; Dr. Carole Heilman, Director of the Division of Microbiology and Infectious Diseases (DMID) at the NIAID; Dr. Regina Rabinovitch, Director of Infectious Diseases for the Bill and Melinda Gates Foundation and Dr. George Whitesides, Woodford L. and Ann A. Flowers University Professor at Harvard University. Dr. Steve Reed from IDRI will serve as the Chair and Dr. Barbara Laughon from NIAID will serve as the Executive Secretary.
About The Lilly TB Drug Discovery Initiative
The Lilly TB Drug Discovery Initiative is a not-for-profit
public-private partnership with a mission to accelerate early-stage drug
discovery by bringing together specialists from around the world for the
systematic exploration of vast, private molecular libraries in search of
new TB treatments. Headquartered in Seattle, The Lilly TB D
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved